News Hub | News Direct

News Release

Freedom Holdings Gives Insight of the New Corporate Focus

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce the new management’s long-term goal in the cannabis arena which completes our plan to re-structuring the company with a productive reorganization in the Cannabis arena. With MEDcann, Inc. as our new majority owned shareholder, the Company is a Medical Cannabis Company focusing on Beverage manufacturing under 420 Beverages which is partners with a 420 - 215 licensed company called the Medical Cannabis, Inc. a subsidiary of MedCann. We are focusing on Research, in medical beverages, overseeing product manufacturing and sales. Our divisions in the cannabis industry, along with their associated products in the medical and health industries plans to Grow, Cultivate, Research and Manufacture CBD and THC beer and soft drinks in the medical marijuana industry with products that help a variety of maladies. Our intent is to conduct and pass Clinical Trials pursuant to offer the credibility needed so we can obtain FDA and Patient Recognition. Since there are over 1000 chemicals in each strain of cannabis it maybe next to impossible to get approval, but we plan to set a precedence and mark the new beginning of history by opening the doors to recognition of the potential future for patient curiosity and satisfaction in treating cancer and the associated pain that accompanies the devastating condition. FDA approval will afford us the ability to pursue Insurance company acceptable to support patient access to our VCO (Visita Care Oil) a remake of the RSO (Rick Simpson Oil). RSO is a cannabis concentrate used for many different medical benefits, including relieving cancer symptoms. Press Release Contact: John Vivian CEO Freedom Holdings, Inc. 260-490-9990 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. +1 260-490-9990

February 24, 2023 08:30 AM Eastern Standard Time

News Release

1606 Corp secures $20 million in financing as it looks to grow through acquisition

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news about the CBD company that is looking for major growth this year through several avenues including acquisitions. To help in that, the company has just announced an equity financing agreement with GHS Investments for up to $20 million. Lambrecht told Proactive more about how he sees the CBD industry as a whole and also the company’s strategy when it comes to acquisitions as it looks to the future and a possible listing on the Nasdaq. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 24, 2023 08:06 AM Eastern Standard Time

Video

News Release

Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals president and CEO Sumit Aggarwal joins Proactive's Natalie Stoberman to discuss the latest update on the clinical study for its lead investigational product candidate ELX-02. Aggarwal said the first batch of patients has now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Up to eight Alport syndrome patients with nonsense mutations in the COL4 gene will be dosed for two months with a three-month follow-up. With this timeline, the company is expected to remain on track to deliver topline clinical results from this trial in the first half of 2023. Contact Details Proactive US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 24, 2023 08:01 AM Eastern Standard Time

Video

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

OKYO Pharma

By David Willey, Benzinga An eye condition that has been described as a common disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over 15% of Americans over 50 and disproportionately affects women and DED patients are not well served by currently approved drugs. It’s concerning facts like these that inspired the biopharmaceutical company OKYO Pharma Ltd. (NASDAQ: OKYO) to develop a drug that can help the millions suffering from DED. DED, a condition often associated with aging, is caused when a tear film dysfunction means tears are unable to provide adequate lubrication for the eyes. Symptoms include a scratchy sensation in the eyes, light sensitivity, blurry vision, and eyesight fatigue. DED can also cause ocular pain from damage to the surface of the eye, and the market surrounding DED treatment is currently worth over $5 billion. DED incidence in the US has been increasing, and there are also extrinsic factors that could be behind the increasing rate of DED in America. As the population ages, the number of people most at risk for DED increases, and lifestyle choices like contact lenses and heavy blue light exposure contribute to dry eyes and eventual ocular damage. DED is a chronic condition, meaning treatments need to be suitable for long-term use, but the drugs currently available on the market don’t appear to be filling this need. Some like Eysuvis have seen success but are strictly a short-term treatment, while others, including Restasis, Xiidra, and Cequa, have discomforting side effects which lead large numbers of patients to not refill their prescriptions. Now, OKYO Pharma is looking to bring real solutions to people suffering from DED through the novel drug it is currently developing, OK-101, which is administered topically as eye drops. The drug’s anti-inflammatory activity treats DED while pain-reducing activity alleviates DED-associated ocular pain. Solving Inflammation And Ocular Pain OKYO Pharma is a London-based drug development company that is looking to bring a new drug to the market. Though drug development is a notoriously slow process, OKYO’s novel OK-101 treatment is seeing rapid development that may get it to market in record time. The team is led by Dr. Gary Jacob, CEO of OKYO Pharma and director of the drug’s development. Dr. Jacob is a drug development veteran with a proven record, as he has already developed and brought to market two Federal Drug Administration (FDA)-approved drugs. Also on the team is Dr. Raj Patil, Chief Scientific Officer who has expertise and years of experience in ophthalmology drug development. Focus is often what separates success from failure in the biotech space, with companies failing when they try to cast their net too wide. On the other hand, OKYO Pharma is laser-focused on the development of its drug OK-101 for DED treatment, and it will be collecting data from its clinical trials that are starting soon. In fact, OKYO received FDA approval to skip its phase one trial and jump straight to its phase two efficacy trials, with the possibility of an accelerated regulatory submission. Pre-clinical animal data indicate that OK-101 reduces both inflammation of the eye and the corneal neuropathic pain which results from nerve damage to the eye caused by DED. There currently isn’t a topical treatment for ocular pain approved by the FDA, which is another reason OKYO Pharma is excited to move ahead with the trials for OK-101. Similar companies in the market include Aldeyra Therapeutics (NASDAQ: ALDX) and Tarsus Pharmaceuticals (NASDAQ: TARS), both of which have a market cap of around $400 million. Want to learn more about what OKYO Pharma is doing to tackle DED and other eye diseases? Visit its website. This article was originally published on Benzinga here. OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR christine@tradigitalir.com Company Website https://okyopharma.com/

February 23, 2023 10:30 AM Eastern Standard Time

74 Million Americans Don’t Have Dental Insurance—Dental Savings Plans Are the Low-Cost Alternative That’s Making It Possible to Get Oral Care Anyway

DentalPlans.com

By Rachael Green, Benzinga A 2022 study in the Journal of Public Health Dentistry reviewed the 2019 data of 4.67 million Medicaid recipients and found that those who received at least five continuous years of preventative dental care were spending 43% less on dental care than those who’d received no preventative care at all. Those savings were in part because they were much less likely to need oral surgery or emergency care for severe pain caused by decay or oral disease. Yet four out of ten Americans delay seeing the dentist, even when they have a toothache or other problem they know should be addressed. The reason? Dental care can be expensive and millions of Americans don’t have dental insurance. But there is some good news. More and more Americans are turning to dental savings plans as an alternative to or supplement for insurance. Here’s how they work and what discounts they provide plan members. How Do Dental Savings Plans Work? When someone joins a dental savings plan, they pay an annual membership fee upfront to join — plans start as low as $80 but typically hover somewhere around $150 per year for an individual. Then, they can go to any participating dentist, show their membership card and they’ll be charged the special discounted rate available on the majority of procedures, every time they go. To choose a plan, they can use a marketplace like DentalPlans.com to shop around and compare plans, similar to the way you’d compare insurance. Choosing the best fit comes down to finding a plan that is accepted by a dentist near you and that includes discounts for the procedures you need. Discounts Can Be Substantial Plans vary but procedures are usually discounted by 10% to 60%. A routine checkup that might normally cost $73 per person, for example, can be reduced to as little as $19 per person, making it much easier to keep up with essential preventative care. Major work like full dentures or dental implants that might normally be prohibitively expensive can be discounted significantly. Discounts Kick In Right Away With insurance, coverage for certain procedures might not kick in for months or even a full year. That means a person with no insurance who finds out they need urgent work done like a root canal or tooth extraction won’t be able to use their benefits, even though they’re paying the premium until that waiting period is over. While Insurance has waiting periods, Dental savings plans do not. Individuals can join any time of year and the discounts kick in as soon as their membership is activated, a process that typically takes about 1-3 business days. There Are No Annual Limits Most dental insurance coverage caps out at $1,000-$2,000 and even the most generous plans cap out at $5,000. Once your dental care for the year hits that annual maximum, your insurance won’t pay for anything else—even if it’s a procedure your plan would normally cover. This means even insured patients have to make tough decisions about whether to delay needed treatments until their maximum resets or skip it altogether in the case of a procedure that costs more than the annual maximum on its own. With a dental savings plan, plan members don’t have that problem. No matter how much or what kind of work they need, they’ll always pay the discounted rate on virtually any procedure. There Are No Exclusions Or Tricky Care Exceptions Because a discount program isn’t the same as insurance, plan members don’t have to worry about being excluded from certain care on the basis of current health conditions. They also don’t have to go through the stress of determining whether a procedure is medically necessary or qualifies for coverage. Better yet, many plans also include steep discounts on cosmetic work like veneers or teeth whitening that many insurers won’t cover at all. So long as the procedure is listed in the savings plan and you go to a participating dentist, you can get the dental care you need at the discounted rate provided in the plan. While no two dental savings plans are the same and they don’t all include the same procedures or dentists, they’re extremely straightforward and it’s easy to understand what you’re getting before you sign up. On DentalPlans.com, for example, you can filter by the procedure as well as location or dentist. This makes it easy to find a program that includes the dental care you actually need. To learn more visit DentalPlans.com This article was originally published on Benzinga here. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

February 23, 2023 09:25 AM Eastern Standard Time

Clear Vision Impact Fund Announces Latest Round of Investments

Siebert Williams Shank

Since its final closing in March 2022, the Clear Vision Impact Fund (Clear Vision or CVIF) has provided loans to minority-owned businesses across the U.S. It has originated loans to seven portfolio companies, including two new investments that closed last month. "The Clear Vision team embraces the opportunity to provide liquidity and growth capital to small and mid-sized businesses that serve communities in a manner that is consistent with our impact mission," said Christopher J. Williams, principal of Clear Vision’s general partner and Chairman of Siebert Williams Shank & Co., LLC. "We are energized that our portfolio companies, which span a range of industries, strive to save jobs and increase job training among underserved communities." "The CVIF loan played a critical role in P&THE Manufacturing Acquisition’s first acquisition of Ross Aluminum. We had to work expeditiously in closing the deal, condensing a timeline that would normally take four to five months down to six to eight weeks at the behest of the previous owner,” said Pancho Hall, CEO and Chairman of P&THE Manufacturing. “Thanks to the professionalism, accuracy, and pure determination of all responsible parties, we were able to finalize the loan and close on this amazing opportunity, which positions us to capitalize on our strategy to gain a collection of world-class enterprises that serve global communities as their minority-business enterprise of choice." “The asset management business needs a big funnel to find innovative solutions that impact the broader society,” said Dabo Horsfall, Founder and CEO of Tensile Investments. “CVIF has been a true growth partner; their approach to investing is fair, their feedback is constructive, and their approach to partnership is genuine. CVIF has supported Tensile’s mission to provide clean mobility solutions that improve the lives of ALL people while developing electric vehicle charging infrastructure in a profitable manner.” “Valeo Networks teamed with the Clear Vision Impact Fund in October 2021 for the purpose of growth through acquisition. As our financing partner, Clear Vision has fueled our acquisition growth, allowing us to double in size by funding three acquisitions in our first year of partnership, making Valeo Networks one of the 50 largest Managed Security Service Providers (MSSPs) in the United States,” said Travis Mack, CEO and Chairman of Valeo Networks. “Clear Vision has been very flexible and worked closely with Valeo to gain a detailed understanding of our business model and acquisition strategy, which helps us to be nimble and efficient during acquisition. We look forward to continuing to work with Clear Vision and continuing our growth to more than $50 million annual revenue over the next 2-4 years to become one of the 10 largest MSSPs nationwide.” “The Clear Vision Impact Fund partnered with Medi-Fare in the immediate aftermath of the COVID-19 pandemic. Whether it is collaborating on enhancing our business through new client targets, crafting impact strategies to increase local hiring, or producing marketing materials, the Clear Vision team has never viewed a task as too small. We look forward to its continued support in 2023 as Medi-Fare scales its production capacity,” said Artis Terrell Jr., CEO of Medi-Fare Drug Pharmaceutical Compounding. “At CVIF, we have been fortunate in continuing to source unique opportunities to support diverse entrepreneurs and investors that not only share our passion for positively impacting underserved communities, but also demonstrate that impact and financial performance are not mutually exclusive,” said Kyle C. Sligar, Chief Credit Officer and Portfolio Manager of the Clear Vision Impact Fund. We look forward to deploying more customized debt solutions for both existing portfolio companies and new prospects as they execute on their growth initiatives.” In addition to providing financing, Clear Vision aims to support portfolio companies by working with them to define and execute on their impact goals, evaluating proposed operational improvements and strategic initiatives, and introducing them to prospective customers and partners, among other things. To date, Clear Vision has provided loans to seven African American-owned businesses, several of which are detailed below. P&THE Manufacturing, headquartered in metro Detroit, is a minority-owned holding company comprised of businesses that provide manufacturing solutions. It differentiates itself in the marketplace as a true owner operator who has experience working in and managing businesses at the senior level ranging from the lower middle market to Fortune 100 companies. Learn more at www.rossal.com. Tensile Investments is an impact driven holding company that provides clean mobility options in transit deserts. It develops smart mobility hubs and funds clean first-last mile transportation. Tensile Investments partners with municipalities and private property owners to create smart mobility hubs by modernizing parking lots and garages to provide electric vehicle (“EV”) fleet parking and charging, electric micro-transit services, clean distributed energy services, public EV charging, and electric micro-mobility services. Learn more at www.tensileinvestments.com. Medi-Fare Drug Pharmaceutical Compounding is a minority-owned 503B pharmaceutical compounding facility registered with the Federal Drug Administration as an Outsourcing Facility. Medi-Fare serves as a partner to hospitals and other healthcare providers to supply much needed medications to help improve positive outcomes for their patients and fulfill the need for the ever-growing number of medicines in shortage or backorder situations. Headquartered in Blacksburg, South Carolina, it serves a range of medical facilities and acts as a health care partner for hospital systems, surgery centers, clinics, and doctor’s offices. Learn more at www.medifaredrug.com. Valeo Networks is a full-service, award-winning Managed Security Service Provider (MSSP) that serves state, county, and municipal markets; small-to-medium businesses; and non-profit organizations. Firmly seated in the top 5% of revenue generating MSSPs nationwide—making it one of the largest MSSPs nationally—Valeo Networks provides solutions in the areas of cybersecurity, compliance, cloud, network infrastructure, and managed IT services. With over 20 years of industry experience, Valeo Networks is headquartered in Rockledge, FL, with additional locations nationwide. Learn more at www.valeonetworks.com. A-1 is an established and fast-growing disaster-response company which provides on-demand resources, services, and logistics during catastrophes. Services include large-loss restoration services, commercial construction, staffing, restoration equipment rental & monitoring, as well as time and material documenting and preparation during natural disasters such as hurricanes, tornadoes, and freezing and flooding events that cause property damage. Headquartered in Charlotte, North Carolina, A-1’s extensive experience and seasoned personnel have allowed it to create a first-of-its-kind national network and partnership program that brings together service providers, supplies, equipment, and labor. Learn more at www.a1disasterresources.com. About the Fund SponsorClear Vision’s sponsor is an affiliate of Siebert Williams Shank, a leading non-bank financial services firm serving clients across industries and asset classes. It is both a minority-owned and women-owned enterprise. SWS Capital Management, an investment adviser affiliated with Siebert Williams Shank, serves as Clear Vision’s investment manager.To learn more about Clear Vision’s closings or investment portfolio, please visit www.clearvisionimpact.com. This press release (“Press Release”) is being published for informational purposes only regarding Clear Vision Impact Fund (“Clear Vision” or “CVIF”). One should not assume an investment in any of the described companies was or will be profitable. The companies listed in this Press Release do not represent all CVIF’s investments. All opinions, estimates and forecasts are based on information as of the date of this Press Release and are subject to change. Certain information contained in this Press Release constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “target,” “project,” “estimate,” “intend,” “continue” or “believe,” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. CVIF has not vetted the companies’ websites and CVIF’s provision of the companies’ website links should not be considered an endorsement of the information presented there. Contact Details Tom Butler +1 646-213-1802 TButler@ButlerPR.com Christian Agredo +1 646-213-0286 CAgredo@ButlerPR.com Company Website https://www.clearvisionimpact.com/

February 22, 2023 09:30 AM Eastern Standard Time

Robotics Has Transformed Many Industries – Is The Food Industry Next?

Blendid

By Faith Ashmore, Benzinga Interested in investing in Blendid’s campaign? Click here to get started. It’s almost impossible to miss how food prices have been rising in the past year due to inflation. Fuel prices have soared, and the cost of common goods like eggs has risen by up to 60%. In addition, geopolitical conflicts like the war in Ukraine are increasing global instability and affecting food supply chains – impacting markets globally. One solution that industry leaders and analysts have identified lies in the expansion of the global food service robotics industry. Looking to technology during times of crisis is not a new trend. The automotive industry has been aided significantly by robotics teams to help automate assembly lines and cut down costs, especially amid recessions. Robots are found in almost every part of a car plant, and it’s estimated that by 2025 as much as 75% of vehicles will ride on robot production lines. Manufacturing in general has been absolutely transformed by robotics, helping manufacturers achieve peak efficiency and productivity. The food industry is no different, but it requires innovative approaches to fully leverage the advantages of robotics. Technology and innovation are crucial to the modern food service industry. Not only does technology help companies lower operating costs but it also expands access to fresh food in more locations. While robotics in food service is still in its relative infancy, the increasing ingredient and labor cost challenges are accelerating their growth to help transform the food service industry as it did manufacturing – and companies like Blendid are leading the charge. Blendid, a robotic and AI-enabled food automation solution company, has seen firsthand the success of a fully autonomous robotic kiosk for smoothies. Their kiosks operate in universities, travel centers, retail stores, and hospitals across the country. The kiosks can operate 24/7, which gives consumers access to healthy and affordable food around the clock while the company is able to maintain low operational costs. The company has seen a 267% revenue increase year-over-year which is unsurprising given the consumer demand for healthy and sustainable food. Not only is the kiosk model contactless, but being open 24/7 increases the accessibility of healthy food. For college students or late-night workers, who typically have limited access to healthier foods, Blendid is changing the landscape of food justice. If projections are to be believed, the food robotics industry is only going to continue to grow. The global market for food robotics was estimated at $2.1 billion in 2022, and the market is projected to reach $4B by 2026. Companies like Blendid will be instrumental in the industry by providing unique experiences and options for consumers on the go. Blendid is currently hosting a raise to further expand its ingenious concept. The company is currently working on expanding to 10 additional geographies in the near future and has 500+ kiosks in contract. Previously, they raised more than $26 million which translated into significant revenue growth. It is clear that the consumer demand is there for the smoothie kiosk model and it’ll be interesting to see how Blendid will continue to be an industry leader. Interested in investing and being a part of their growth story? Click here to read more about Blendid’s raise and how to invest! This article was originally published on Benzinga here. Sunnyvale-based Blendid is revolutionizing the future of food service with its proprietary food automation platform (foodOS™), which efficiently and safely prepares and serves a range of healthy, fresh, and delicious food. A pioneer of the future of food service, Blendid's first concept in the market is an autonomous, contactless kiosk that uses robotics, machine vision, artificial intelligence, and healthy ingredients to create delicious smoothies that are customized to meet the unique health and dietary preferences of each consumer. Founded in 2015 by seasoned Silicon Valley entrepreneurs Vipin Jain, Venki Avalur, and Vijay Dodd, Blendid is improving the consumer experience by offering safe, cost-effective, and personalized food on-demand, while also reducing complexities and costs for the operators. Blendid has raised more $20M to date from a mix of venture and crowdfunding investors and is currently raising its Series B investment round. Visit www.startengine.com/blendid for more information and to invest in the future of food service automation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information. Contact Details Erica Camilo 344130@email4pr.com Company Website http://www.blendid.com

February 22, 2023 09:00 AM Eastern Standard Time

News Release

Predictive Oncology appoints Pamela Bush as new chief business officer

Predictive Oncology Inc.

Predictive Oncology's new chief business officer Pamela Bush joined Proactive's Natalie Stoberman to share her plans for her new role with the company. Bush will lead all business development, partnering and growth strategies for Predictive Oncology and spearhead the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. The new CBO previously served as senior vice president of strategic sales and business development at the company. In that role, she was instrumental in guiding Predictive Oncology's strategic direction, expanding its product offerings and launching commercialization efforts for its flagship technology platform. Contact Details Proactive US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 21, 2023 02:04 PM Eastern Standard Time

Video

News Release

ChitogenX partners with Polytechnique Montréal on federal grant for ORTHO-R regenerative treatment

ChitogenX Inc

ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,000 grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec and will collaborate with Polytechnique Montréal throughout the four-year grant period to advance the scientific development, expand the scope of indications, develop new biomaterials for regenerative medicine and accelerate the commercial readiness of its flagship ORTHO-R technology platform. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 21, 2023 01:53 PM Eastern Standard Time

Video

Healthcare

Freedom Holdings Gives Insight of the New Corporate Focus

1606 Corp secures $20 million in financing as it looks to grow through acquisition

Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

74 Million Americans Don’t Have Dental Insurance—Dental Savings Plans Are the Low-Cost Alternative That’s Making It Possible to Get Oral Care Anyway

Clear Vision Impact Fund Announces Latest Round of Investments

Robotics Has Transformed Many Industries – Is The Food Industry Next?

Predictive Oncology appoints Pamela Bush as new chief business officer

ChitogenX partners with Polytechnique Montréal on federal grant for ORTHO-R regenerative treatment